文献速递神经肿瘤神经重症

胶质母细胞瘤中的软脑膜病变:终局还是机会?

Leptomeningeal disease in glioblastoma: endgame or opportunity?
PubMed 文献 · J Neurooncol · 2021-10-08

本综述遵循PRISMA标准系统检索PubMed和OVID数据库,纳入成人胶质母细胞瘤合并软脑膜病变(LMD)的研究。LMD发生率最高达21%,未治疗生存仅1.6-3.8个月,治疗可显著延长生存至11.7个月,但尚无某一种辅助或手术治疗优于其他方案。

要点

  • 胶质母细胞瘤LMD发生率上升,报告高达21%。
  • 未治疗LMD生存仅1.6-3.8个月,治疗可显著改善生存。
  • 尚无共识或标准治疗,需个体化决策。

核心结论

  • 证据仍缺乏且无共识,但治疗显示改善生存趋势,应个体化考虑。
  • 需进一步研究以建立标准治疗。

研究设计与样本

  • 系统综述,遵循PRISMA标准检索PubMed和OVID数据库。
  • 纳入成人胶质母细胞瘤合并LMD的研究。

主要发现

  • LMD发生率上升,报告高达21%。
  • 未治疗总生存仅1.6-3.8个月。
  • 治疗显著改善总生存,一项研究达11.7个月。
  • 无一种辅助或手术治疗显著优于其他。

关键数值与推荐

  • 直接治疗包括化疗(标准、抗血管生成、鞘内、免疫)和放疗。
  • 脑积水可置入脑室腹腔分流管处理,但处理脑积水与鞘内化疗存在挑战。

临床怎么用

  • 治疗应基于个体化评估考虑,旨在改善生存。
  • 脑积水需分流处理,同时需协调鞘内化疗。

局限性

  • 证据缺乏,无共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glioblastoma is an aggressive cancer with a notoriously poor prognosis. Recent advances in treatment have increased overall survival, though this may be accompanied by an increased incidence of leptomeningeal disease (LMD). LMD carries a particularly severe prognosis and remains a late stage manifestation of glioblastoma without satisfactory treatment. The objective of this review is to survey the literature on treatment of LMD in glioblastoma and to more fully characterize the current therapeutic strategies. METHODS: The authors performed a systematic review following PRISMA criteria on PubMed and OVID databases. Articles that included adult patients with LMD from glioblastoma were retrieved and reviewed. RESULTS: LMD in glioblastoma patients is increasing in incidence, with reports of up to 21%. The overall survival without treatment is alarmingly brief, with patients surviving between 1.6-3.8 months. All studies showed that treatment does improve overall survival significantly, increasing to 11.7 months in one study. However, no one adjuvant or surgical therapy has been shown to improve survival in LMD significantly over another. Direct treatment methods include chemotherapy (standard, anti-angiogenic, intrathecal, immunotherapy), and radiation. Hydrocephalus is a complication in LMD that can be treated with ventriculoperitoneal shunt placement, however treating hydrocephalus and delivering intrathecal chemotherapy is a challenge. CONCLUSION: Though evidence remains lacking and there is no consensus, treatments show a trend towards improving survival and should be considered on a case-by-case basis. Further studies are necessary in the pursuit of a standard of care.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Akmal S, Ginalis EE, Patel NV, et al. Leptomeningeal disease in glioblastoma: endgame or opportunity? J Neurooncol. 2021. PMID: 34623599. doi:10.1007/s11060-021-03864-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。